- Home
- EOD vs PBYI Comparison
EOD vs PBYI Comparison
Compare EOD & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOD
- PBYI
- Stock Information
- Founded
- EOD 2007
- PBYI 2010
- Country
- EOD United States
- PBYI United States
- Employees
- EOD N/A
- PBYI N/A
- Industry
- EOD Investment Managers
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- EOD Finance
- PBYI Health Care
- Exchange
- EOD Nasdaq
- PBYI Nasdaq
- Market Cap
- EOD 245.9M
- PBYI 263.4M
- IPO Year
- EOD N/A
- PBYI N/A
- Fundamental
- Price
- EOD $5.63
- PBYI $5.08
- Analyst Decision
- EOD
- PBYI Strong Buy
- Analyst Count
- EOD 0
- PBYI 1
- Target Price
- EOD N/A
- PBYI $7.00
- AVG Volume (30 Days)
- EOD 118.1K
- PBYI 644.5K
- Earning Date
- EOD 01-01-0001
- PBYI 11-06-2025
- Dividend Yield
- EOD 9.28%
- PBYI N/A
- EPS Growth
- EOD N/A
- PBYI 59.87
- EPS
- EOD N/A
- PBYI 0.74
- Revenue
- EOD N/A
- PBYI $211,995,000.00
- Revenue This Year
- EOD N/A
- PBYI N/A
- Revenue Next Year
- EOD N/A
- PBYI N/A
- P/E Ratio
- EOD N/A
- PBYI $6.83
- Revenue Growth
- EOD N/A
- PBYI N/A
- 52 Week Low
- EOD $3.73
- PBYI $2.32
- 52 Week High
- EOD $4.71
- PBYI $6.12
- Technical
- Relative Strength Index (RSI)
- EOD 39.53
- PBYI 50.17
- Support Level
- EOD $5.63
- PBYI $4.76
- Resistance Level
- EOD $5.72
- PBYI $5.10
- Average True Range (ATR)
- EOD 0.07
- PBYI 0.42
- MACD
- EOD -0.02
- PBYI -0.03
- Stochastic Oscillator
- EOD 17.97
- PBYI 32.69
About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.